Lung Cancer Europe

Tweet this page
<
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 16 Jun 2021
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

250,000€

Financial year: Jan 2020 - Dec 2020

Lobbyists (Full time equivalent)

3.25 Fte (8)

Lobbyists with EP accreditation

0

High-level Commission meetings

1

Lobbying Costs over the years

  • Info

    Lung Cancer Europe   (LuCE)

    EU Transparency Register

    112188222754-11 First registered on 21 Jul 2016

    Goals / Remit

    LuCE is committed at increasing the survival rates and the improvement of health related quality of life of lung cancer patients in Europe.

    Our 4 Key Goals:
    Create awareness of lung cancer
    Access to the best possible treatment
    Reduce mortality - early detection
    Equality of care throughout Europe

    Main EU files targeted

    We work with our partner groups in Europe to support patients, survivors and caregivers, to raise awareness on the lack of funds for lung cancer and one of our main target is advocating for receiving an equal access to LC diagnostics and treatments and for receiving the best LC treatments across all EU countries. In the past 4 years, LuCE organized 4 events hosted by MEPs to highlight the big inequieties still persisting for European lung cancer patients. We still consider these topics crucial, and because no so many tangible steps ahead were made, we are ready to organize a new event in EU Parliament, a roundtable.

    Address

    Head Office
    c/o ETOP C/O IBCSG -
    Effingerstrasse 40
    Bern 3008
    SWITZERLAND
  • People

    Total lobbyists declared

    8

    Employment timeLobbyists
    100%1
    50%2
    25%5

    Lobbyists (Full time equivalent)

    3.25

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    III - Non-governmental organisations

    Subcategory

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    ECCO
    ECPC
    EPF
    IASLC
    ECL
    EPHA
    ELF/ERS

    Member organisations

    Patientforeningen Lungekræft
    Suomen Syöpäpotilaat
    Association de L air
    Patients en Reseau/Mon Reseau Cancer du Poumon
    Bundesverband Selbsthilfe Lungenkrebs e.V.
    Landesverband Baden-Württemberg für Lungenkrebskranke und deren Angehörige e.V
    Fairlife Lung Cancer Care
    K.E.F.I. of Athens – Association of Cancer Patients of Athens
    Lélek-zet Egyesület
    Israeli Lung Cancer Foundation
    Associazione Insieme per i pazienti di Oncologia Polmonare IPOP ONLUS
    European School of Oncology
    Women Against Lung Cancer in Europe
    Dzivibas Koks
    Longkanker Nederland
    Lungekreftforeningen
    Stowarzyszenie Walki z Rakiem Płuca
    Pulmonale
    Community Health Association
    Federatia Asociatiilor Bolnavilor de Cancer din Romania
    Društvo onkoloških bolnikov Slovenije
    Asociación Española de Afectados por Cáncer de Pulmón
    Fundación Más Que Ideas
    Lungecancerförbundet Stödet
    European Thoracic Oncology Platform
    National Lung Cancer Forum for Nurses

  • Financial Data

    Closed financial year

    Jan 2020 - Dec 2020

    Lobbying costs for closed financial year

    250,000€

    Other financial info

    nothing relevant

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    - 18/11/2014 " Lung Cancer Europe: reccommandations from patients and experts on lung cancer misperceptions" event organized by Lung Cancer Europe (LuCE)hosted by MEP Ms Liese

    18/11/2014 Presentation and circulation of the first position paper in Lung Cancer

    CALLS TO ACTION:
    1) New guidelines on Lung cancer screening programs
    • Putting guidelines in place that will allow Member States to set-up quality assured early detection programmes for lung cancer, as has already been the case with breast and colorectal cancer as a means to bring down patient mortality.

    2) Continued Funding for Innovative Research
    . Ensuring that EU funds for research and innovation are earmarked towards supporting the development of innovative and life-changing new treatments for lung cancer patients.

    10/11/2015 "The future of the fight against lung cancer" Event organised by Lung Cancer Europe (LuCE) *
    Hosted by Cristian Busoi, EPP MEP and Dr. Philippe de Backer, ALDE MEP

    10 November |ROOM 6Q1| from 14.00 to 16.00
    PANEL I - Novel research findings for lung cancer
    PANEL II - Patients’ initiatives
    PANEL III - Fighting lung cancer: the role of the EU vs measures needed at Member State level

    10/11/2015 Presentation and circulation of the second position paper in Lung Cancer

    CALLS TO ACTION:
    1) Early diagnosis
    Promote screening and diagnosis guidelines for lung cancer with evidence-based
    recommendations.
    · Raise awareness and education on the symptoms of lung cancer among the general public.
    · Improved training and knowledge among general practitioners. Because

    2) Access to molecular testing and innovative treatments
    . Ensure the access to molecular testing and novel therapies for patients.
    · Collect and publish information about testing and treatment access across Europe.
    · Stimulate the development and accreditation of lung cancer specialized centers in Europe
    · Create a single European System dedicated to the evaluation the benefits of new drugs.
    Position Papers on lung cancer challenges
    - Report on inequities in EU countries
    - Workshops in the EU Parliament
    - Collaboration with other NGO and clinical stakeholders in Europe on health issues

    3) Research and development of new medicines
    . Ensure funds continue to be available for research and innovation in the field of lung cancer.
    · Avoid inequalities in access to clinical trials across Europe, and facilitate the movement of European citizens to participate in clinical trials.
    · Strengthen patient involvement in the R&D, providing training and education about this process.

    4)Psychological help
    . Provide a document stating what the basic help from the national system should consist of.
    · Ensure funds for training for medical healthcare professionals on how to share information with cancer patients.

    16.11.2016- On November 16th 2016, event at the European Parliament (Brussels) to raise awareness among different stakeholders and get their commitment with lung cancer challenges. This event is held in collaboration with the Association of European Cancer Leagues (ECL) and it is hosted by MEP Alojz Peterle

    November 2017. Launching at the European Parliament (Brussels) of our 2nd report: Disparities in diagnosis, care and treatment Access.

    November 2018. Launching at the European Parliament (Brussels) of our 3rd report : Clinical trials and lung cancer.

    November 2019. Launching at the European Parliament ( Brussels) of our 4th report: Early diagnosis and screening on lung cancer

    Other activities

    None declared

  • Meetings

    Meetings

    1 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    • Date 07 Aug 2023 Location online
      Subject Online meeting with Lung Cancer Europe on Europe’s Beating Cancer Plan
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Attending
      • Tove Ernst (Cabinet member)
      • Stella Kyriakides (Commissioner)
Download this datacard